Patent Use Code
Recent Publications
5 IP Rules to Know to Protect Your Business in the United States (article in French)
Coaching INPI Newsletter
Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
April 28-30, 2024
November 16, 2023 - In-Person in Munich
October 27, 2023
Reprinted with permission: Article first published in Intellectual Property Management, Vol. 61 (No. 1), p. 17-22 (2011), issued by the Japan Intellectual Property Association.
This article addresses significant consequences of the decision by the Federal Circuit in Novo Nordisk A/S v. Caraco Pharmaceutical Laboratories, Ltd. in April 2010. As a general rule, patents on new indications have traditionally not been successful in preventing generic entry into the market. However, the Federal Circuit decision indicates that NDA holders who have listed in the Orange Book a method of use or indication patents could successfully maintain exclusivity through the expiration date of the method of use or indication patents by broadly writing narratives in their patent use codes.
The narratives should cover not only the patented method of use, but all methods of use for the listed drug. By including such broad narratives in the patent use codes, it may be possible for an NDA holder to prevent a generic company from using the statement viii “carve out provisions” and force the generic company to challenge the patent with a paragraph IV statement. All NDA holders should review their Orange Book listings to determine whether they have method of use patents which have been properly listed in the Orange Book and whether the patent use codes should be revised in light of the decision.
Coaching INPI Newsletter